{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-341315","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2026-08-10T12:06:21+00:00","discovered_at":"2026-08-10T12:10:05.343156+00:00","generated_at":"2026-08-10T12:10:33.547792+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Cogent reports Q2 net loss $96.4M; bezuclastinib PDUFA dates set for Nov/Dec 2026","bullets":["Net loss $96.4M vs $73.5M in Q2 2025; R&D $70.8M, G&A $31.8M.","Cash $792.3M at June 30, 2026; pro forma $865.9M with $73.6M ATM proceeds, funds into late 2028.","FDA accepted NDA for bezuclastinib+sunitinib in GIST with priority review; PDUFA Nov 30, 2026.","AdvSM NDA submitted June 30; NonAdvSM PDUFA Dec 30, 2026; APEX trial 65% ORR.","PEAK trial: HR 0.50, mPFS 16.5 vs 9.2 months, ORR 46% vs 26%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-341315","json":"https://secwatch.observer/filing/0001193125-26-341315.json","markdown":"https://secwatch.observer/filing/0001193125-26-341315.md","text":"https://secwatch.observer/filing/0001193125-26-341315.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000119312526341315/0001193125-26-341315-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000119312526341315/cogt-20260810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T12:10:33.547792+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}